Related Experiment Video
Updated: May 27, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells
Oshrat Attar-Schneider1, Liat Drucker, Victoria Zismanov
1Oncogenetic Laboratories, Meir Medical Center, Kfar Saba, Israel.
Abstract:
Multiple myeloma (MM), a malignancy of plasma cells, remains fatal despite introduction of novel therapies, partially due to humoral factors, including vascular endothelial growth factor (VEGF), in their microenvironment. The aim of this study was to explore the efficacy of anti-VEGF treatment with bevacizumab directly on MM cells. Particular attention was directed to the affect of VEGF inhibition on protein translation initiation. Experiments were conducted on MM cells (lines, bone marrow (BM) samples) cultured on plastic. Inhibition of VEGF was achieved with the clinically employed anti-VEGF antibody, bevacizumab, as a platform and its consequences on viability, proliferation, and survival was assessed. VEGF downstream signals of established importance to MM cell biology were assayed as well, with particular emphasis on translation initiation factor eIF4E. We showed that blocking VEGF is deleterious to the MM cells and causes cytostasis. This was evidenced in MM cell lines, as well as in primary BM samples (BM MM). A common bevacizumab-induced attenuation of critical signaling effectors was determined: VEGFR1, mTOR, c-Myc, Akt, STAT3, (cell lines) and eIF4E translation initiation factor (lines and BM). ERK1/2 displayed a variegated response to bevacizumab (lines). Utilizing a constitutively Akt-expressing MM model, we showed that the effect of bevacizumab on viability and eIF4E status is Akt-dependent. Of note, the effect of bevacizumab was achieved with high concentrations (2 mg/ml), but was shown to be specific. These findings demonstrate that bevacizumab has a direct influence on major pathways critically activated in MM that is independent from its established effect on angiogenesis. The cytostatic effect of VEGF inhibition on MM cells underscores its potential in combined therapy, and our findings, regarding its influence on translation initiation, suggest that drugs that unbalance cellular proteostasis may be particularly effective.
Insights
Blocking vascular endothelial growth factor (VEGF) with bevacizumab directly harms multiple myeloma (MM) cells, causing cytostasis. This inhibition affects key signaling pathways and protein translation initiation, suggesting potential for combination therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Multiple myeloma (MM) is a fatal plasma cell malignancy.
- Tumor microenvironment factors, like vascular endothelial growth factor (VEGF), contribute to MM progression.
- Novel therapies are needed to overcome resistance and improve MM patient outcomes.
Purpose of the Study:
- To investigate the direct anti-cancer effects of anti-VEGF treatment (bevacizumab) on multiple myeloma cells.
- To determine the impact of VEGF inhibition on protein translation initiation in MM.
- To explore the downstream signaling pathways affected by bevacizumab in MM.
Main Methods:
- Experiments utilized MM cell lines and primary bone marrow (BM) samples.
- VEGF inhibition was achieved using the anti-VEGF antibody, bevacizumab.
- Assessed MM cell viability, proliferation, survival, and key signaling pathways including eIF4E.
Main Results:
- Bevacizumab treatment demonstrated a direct cytostatic effect on MM cell lines and primary BM samples.
- Inhibition of VEGF by bevacizumab attenuated critical signaling pathways: VEGFR1, mTOR, c-Myc, Akt, STAT3, and eIF4E.
- The effect of bevacizumab on MM cell viability and eIF4E was dependent on Akt signaling.
Conclusions:
- Bevacizumab directly impacts key MM pathways, independent of its anti-angiogenic effects.
- VEGF inhibition shows potential as a therapeutic strategy for multiple myeloma, particularly in combination therapies.
- Targeting protein translation initiation via VEGF inhibition may offer a novel approach for MM treatment.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
The Intrinsic Apoptotic Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Tumor Immunotherapy

